The estimated Net Worth of Mark A Collar is at least $4.47 Million dollars as of 13 March 2023. Mr. Collar owns over 10,000 units of Atricure Inc stock worth over $2,713,430 and over the last 17 years he sold ATRC stock worth over $1,559,534. In addition, he makes $192,478 as Independent Director at Atricure Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Collar ATRC stock SEC Form 4 insiders trading
Mark has made over 41 trades of the Atricure Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of ATRC stock worth $93,000 on 13 March 2023.
The largest trade he's ever made was exercising 25,000 units of Atricure Inc stock on 18 January 2018 worth over $332,750. On average, Mark trades about 1,837 units every 71 days since 2008. As of 13 March 2023 he still owns at least 100,871 units of Atricure Inc stock.
You can see the complete history of Mr. Collar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Collar biography
Mark A. Collar serves as Independent Director of the Company. Mr. Collar has served as one of our directors since February 2008. Mr. Collar is the owner of Collar, Ltd., an investment and consulting business. Mr. Collar retired in 2008 as an officer within the Procter and Gamble Company where his roles included President of the Global Pharmaceuticals and Personal Health business. Mr. Collar joined Procter and Gamble in 1975 as a sales representative, then moved into advertising, and subsequently assumed roles of progressive responsibility within the Health and Personal Care, Beauty Care, New Business Development, Pharmaceuticals and Personal Health Care Products divisions over his 32-year career. Mr. Collar recently served as a director of First Financial Bancorp; Enable Injections, a privately-held start-up company focusing on high volume injection devices for biologic drugs; and as Chairman and Director of Marketing at TTRC, LLC (Invisible Ink Tattoo Removers), a national tattoo removal chain. Mr. Collar also serves in director and advisory roles in several philanthropic, academic and economic development organizations. Mr. Collar received his B.S. from Northern Illinois University.
What is the salary of Mark Collar?
As the Independent Director of Atricure Inc, the total compensation of Mark Collar at Atricure Inc is $192,478. There are 10 executives at Atricure Inc getting paid more, with Michael Carrel having the highest compensation of $5,829,780.
How old is Mark Collar?
Mark Collar is 67, he's been the Independent Director of Atricure Inc since 2008. There are 2 older and 10 younger executives at Atricure Inc. The oldest executive at Atricure Inc is Sven Wehrwein, 69, who is the Independent Director.
What's Mark Collar's mailing address?
Mark's mailing address filed with the SEC is 2 OXFORD AVENUE, , TERRACE PARK, OH, 45174.
Insiders trading at Atricure Inc
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie..., and Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
What does Atricure Inc do?
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
What does Atricure Inc's logo look like?
Complete history of Mr. Collar stock trades at Atricure Inc and First Bancorp
Atricure Inc executives and stock owners
Atricure Inc executives and other stock owners filed with the SEC include:
-
Michael Carrel,
President, Chief Executive Officer, Director -
Douglas Seith,
Chief Operating Officer -
Salvatore Privitera,
Chief Technology Officer -
Justin Noznesky,
Senior Vice President, Marketing and Business Development -
Scott Drake,
Independent Chairman of the Board -
Sven Wehrwein,
Independent Director -
Mark Lanning,
Independent Director -
B. Kristine Johnson,
Independent Director -
Robert White,
Independent Director -
Regina Groves,
Independent Director -
Mark Collar,
Independent Director -
Karen Prange,
Independent Director -
Daniel Florin,
Independent Director -
Angela Wirick,
Chief Financial Officer -
Shlomo Nachman,
Director -
Karen P Robards,
Director -
Elizabeth D Krell,
Director -
Richard M Johnston,
Director -
Michael D Hooven,
Director -
Andrew L Lux,
V.P. & Chief Operating Officer -
Group I, Llc Murphy Michael...,
-
M. Andrew Wade,
CFO -
Tonya Austin,
Chief Human Resources Officer -
Deborah L Morley,
VP Clinical Affairs -
Lee R Wrubel,
Director -
Maureen Shaffer,
Vice President Marketing -
Jon A Sherman,
VP Product Development -
Elsa Chi Abruzzo,
VP; Regulatory&ClinicalAffairs -
Alan L Kaganov,
Director -
Richard S Walsh,
Vice President; Sales -
Management Group Viii L L C...,
-
Management Group Viii L L C...,
-
Stephen S Cambridge,
Vice President; Sales -
Management Group Viii L L C...,
-
Thomas J Etergino,
Vice President and CFO -
Norman R Weldon,
Director -
Patricia J Kennedy,
VP, GM, International -
James L Lucky,
VP; QA & Healthcare Compliance -
Management Group Viii L L C...,
-
David J Drachman,
President and CEO -
Richard Mcamden Partners St...,
-
Richard Mcamden Partners St...,
-
Donald C Harrison,
Director -
Group I, Llc Donoghue Danie...,
-
Stewart W Strong,
Vice President US Sales -
Management Group Viii L L C...,
-
Frederick Preiss,
Vice President; Operations -
Julie A Piton,
VP and CFO -
Deborah H Telman,
Director -
Karl S. Dahlquist,
Chief Legal Officer -
Vinayak Doraiswamy,
Chief Scientific Officer -
Maggie Yuen,
Director -
Deborah Lee Yount,
Chief Human Resources Officer